VK2809

· Viking Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for VK2809, covering 2021-04-26 to 2024-06-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH [Phase 2]